Petr Arenberger

Definition of treatment goals for moderate to severe psoriasis: a European consensus

Ulrich Mrowietz, Knud Kragballe, Kristian Reich et al. · Archives of Dermatological Research · 2010 · 886 citations · Full text

Medicine, Dermatology, Pharmacotherapy +14

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà et al. · The Lancet Oncology · 2020 · 525 citations

Medicine, Immunology, Oncology +17

European S3‐Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – <scp>EDF</scp> in cooperation with <scp>EADV</scp> and <scp>IPC</scp>

Alexander Nast, Paolo Gisondi, Anthony D. Ormerod et al. · Journal of the European Academy of Dermatology and Venereology · 2015 · 395 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld et al. · European Journal of Cancer · 2017 · 284 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason Chesney, Antoni Ribas, Georgina V. Long et al. · Journal of Clinical Oncology · 2022 · 284 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17